Currently Viewing:
AMCP 2017
Analyzing the Near-Term Pipeline for Specialty Drugs
March 28, 2017
Dr Aimee Tharaldson Highlights Two Key Drugs for 2017
March 28, 2017
Effectively Moving Toward Value-Based Care
March 28, 2017
Susan A. Cantrell on the Evolution of Value Frameworks
March 28, 2017
Currently Reading
Dr Liz Zhou Explains Basal Insulin Switching Study on Toujeo
March 28, 2017
The Unsustainably Big Business of Healthcare
March 29, 2017
Dr Matthew Pickering: How Quality Measures Are Created and Implemented
March 29, 2017
Addressing the Affordability Issue of Novel Treatments
March 29, 2017
Dr Clifford Goodman Outlines Takeaways From a Health Economic Case Study on Repatha
March 30, 2017
Dr Doug Hillblom on the State of e-Prescribing and Remaining Barriers
March 30, 2017
Cardiovascular Outcome Trials: How Misinterpretation of Statistics Can Affect Clinical Practice
March 30, 2017
Repatha Offers Additional LDL-C Reduction in a Convenient Dosage Form
March 30, 2017
ACA Repeal and Other Healthcare Issues on the Trump Administration's Agenda
April 03, 2017
The Latest in the Move to Value-Based Reimbursement and Remaining Challenges
April 04, 2017
Susan Cantrell: Uncertainty Is Affecting Everyone in Healthcare
April 11, 2017
Dr Aimee Tharaldson Discusses 2 New Treatments for Tardive Dyskinesia
April 12, 2017
Dr Gail Bridges Explains the High Real-World Cure Rate for HCV
April 17, 2017
Dr Richard Willke Previews ISPOR 2017 in Boston
April 18, 2017
Dr Matthew Pickering Discusses Development, Implementation of Quality Measures
April 20, 2017
Dr Doug Hillblom Expects Evolution of e-Prescribing to Continue
April 22, 2017
Dr Aimee Tharaldson: We're Keeping an Eye on Future NASH Treatments
April 27, 2017
Susan A. Cantrell Outlines Concerns and Opportunities for Managed Care
May 01, 2017
The Importance of Ethical Committees in the Evolving Healthcare Environment
May 11, 2017
Dr Lou Garrison on the Discussions Surrounding Outcomes-Based Arrangements
May 17, 2017

Dr Liz Zhou Explains Basal Insulin Switching Study on Toujeo

Liz Zhou, MD, director of evidence-based medicine at Sanofi Medical Affairs outlined the purpose of a study on real-world results of comparing basal insulin dose changes in type 2 diabetes patients using Lantus who either stay on Lantus or switch to Toujeo.


Liz Zhou, MD, director of evidence-based medicine at Sanofi Medical Affairs outlined the purpose of a study on real-world results of comparing basal insulin dose changes in type 2 diabetes patients using Lantus who either stay on Lantus or switch to Toujeo.

Transcript

Explain the research rationale of the EDITION 1 & 2 trials.

As we all know, insulin glargine 300, which is called Toujeo, was approved in the US in early 2015, and in EDITION 1 and 2 trials, both of them are looking at basal switch population. EDITION 1 trial are patients on basal plus meal-timing insulin, and EDITION 2 is basal plus [oral antidiabetic drug]. For both of those in those trials, we can see that patients randomized to Toujeo use 10% more basal insulin compared to patients randomized to Lantus. But how does insulin dose differ between Toujeo and Lantus in the real-world setting is the question that we are hoping to examine in this study. We are looking at Optum Clinformatics data, which is a claims database to answer this question.

How did real-world results follow-up on and expand previous trials?

In this study, we are comparing basal insulin dose change in type 2 diabetes patients who are using Lantus in prior who either switch to Toujeo or remain on Lantus and we are looking specifically into the percent change in daily average consumption, which is called “day con,” in the inpatient from baseline to follow-up. What we did is we matched two cohorts in demographics and clinical characteristics, which is trying to mimic the setting the EDITION 1 and 2 trials, because of the 2 arms. What we have found in the study is that compared to continuing on Lantus, switching to Toujeo is not associated with higher basal insulin dose, and we also observed similar change in A1C and day con between the 2 cohorts. So this is slightly different from what we see in the clinical trial setting, but that’s what we observed in the real-life data. And that’s, I think, a lot of the questions on the payer’s or clinician’s mind.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!